Patients
Seventy-four newly diagnosed pediatric BCP-ALL patients
(aged<18 years) with
IKZF1 gene deletions, who underwent initial treatment in our institution
between June 2014 and January 2018 were included in this study. All
patients met the morphology-immunology-cytogenetics-molecular (MICM)
criteria [4]. The level of IKZF1 Δ2-8/ALB
deletions in bone marrow (BM) samples were detected by multiplex
real-time quantitative PCR (RQ-PCR), as described in a previous study[5]. A patient with a IKZF1 deletion was defined
as having IKZF1 Δ2-8/ALB deletions of ≥ 0.01% of the BM sample at
diagnosis. Clinical characteristics, laboratory data, and treatment
outcomes were analyzed. The study was approved by the Ethics Committee
of Peking University People’s Hospital, and the guardians of all
patients provided written informed consent.